Lifecare Asa · OSL:LIFE
Lifecare Asa — Investor Presentation (April 2025)
21 slides from Lifecare Asa's investor presentation, April 2025
Slide 1: Transforming diabetes care
April 2025 Transforming diabetes care Next-generation continuous glucose monitoring
Slide 2: Disclaimer
Disclaimer The information in this presentation has been prepared by Lifecare (the “Company”). This presentation does not constitute a recommendation regarding any securities of the Company. By accepting to attend this presentation and/or receive this information, you agree to be bound by the follow
Slide 3: High-growth MedTech opportunity
High-growth MedTech opportunity Next-generation ~ USD 5 billion Capital efficient path diabetes medtech addressable market to commercialization Implantable sensors for CGM: small, CGMs the fastest growing diabetes tech Partner-led GTM enabling fast ramp up, long-lasting and calibration-free segment,
Slide 4: Diabetes – an unresolved, growing global health crisis
Diabetes – an unresolved, growing global health crisis Diabetes is a chronic trillion-dollar health care challenge that will continue to rise over the coming years. In 2024, 12% of global health expenditure was spent on diabetes ~600 million people are living with diabetes globally, of which 110 mil
Slide 5: A tipping point for continuous glucose monitoring
A tipping point for continuous glucose monitoring (CGM): more patients, broader use, bigger impact 2 million New Type 1 CGM users globally in 2024 First ever CGM recommendation for Type 2 diabetes in American Diabetes Association 2025 Standards of Care Historic high # of publications related to cont
Slide 6: CGMs have become the de facto standard for diabetes management
CGMs have become the de facto standard for diabetes management – the future is “inject and forget” The past The present The future Pin prick blood glucose Lifecare seamless CGMs – Body-worn CGMs monitoring inject and forget 6
Slide 7: CGMs the fastest growing diabetes tech segment with 12.5% CAGR
CGMs the fastest growing diabetes tech segment with 12.5% CAGR estimated 2022-2030 CGM market size: North America and Europe 35 30 25 20 $30bn+ USD billion 15 Market opportunity in Europe and North 10 America by 2035 5 0 2022e 2025e 2030e 2035e Assuming CGM penetration of 90% in North America and 67
Slide 8: Implantables set to be the fastest growing segment within CGM tech
Implantables set to be the fastest growing segment within CGM tech going forward Implantable CGM market size 5 16% 14% 4 3 12% 10% $5bn+ USD billion Market opportunity in 8% Europe and North 2 6% America by 2035 4% 1 2% 0 0% 2025e 2030e 2035e So urce: Sen seonic company r eport, IDF Diabetes Atlas 2
Slide 9: The future of CGM: what sets Lifecare apart
The future of CGM: what sets Lifecare apart Existing CGM First implantable Lifecare Lifecare systems current product next steps Dexcom, Senseonics Lifecare Lifecare Medtronic, Abbott (Eversense) 7 – 15 days 365 days 180 days 550 days Body-worn patch Small capsule Small capsule Grain of rice Glucose
Slide 10: The osmotic advantage
The osmotic advantage High accuracy and convertibility Osmotic pressure 100% linked to glucose variations with potential for superior accuracy and consistency Proven and interference-resistant High stability in real-world use and less affected by external substances (e.g., food, drinks, medications)
Slide 11: Translating rapid market growth into Lifecare value
Translating rapid market growth into Lifecare value Peak revenue potential (USD million) $2 000 Base case peak revenue: ~ USD 900 $1 800 million on implantable penetration of $1 600 15% and Sencell market share of 25% $1 400 Conservative peak revenue: ~ USD 500 USD million $1 200 $1 000 million. Opt
Slide 12: Pet market offers fast regulatory path and revenue potential
Pet market offers fast regulatory path and revenue potential USD 1 billion market opportunity (2 million dogs) Fast regulatory path to commercial launch Q4 2025 Utilizes existing tech and production capabilities Positive impact on human market readiness Peak revenue opportunity of USD 40 million Pot
Slide 13: Focused, capital efficient path to commercialization
Focused, capital efficient path to commercialization Key developments to date 2025 2026 2027 • In-vitro tests confirm efficacy of miniaturized sensors • Human study confirms accuracy with 9.6% MARD Pre-CE study CE mark European launch • Biocompatibility and longevity study with (human) for humans CG
Slide 14: Scalable, partner-driven B2B model enabling fast ramp-up
Scalable, partner-driven B2B model enabling fast ramp-up Sales, marketing and Sensor R&D and design Production and assembly distribution • Pilot operational • Lifecare licenses technology to • Proprietary Sencell sensor based • Automated manufacturing global pharma/medtech partners on osmotic pressu
Slide 15: Additional financing closely tied to near-term value inflection points
Additional financing closely tied to near-term value inflection points and commercialization Capital uses Financing Focused on R&D and operational scale-up: 70%+ of 2025–2027 Equity Grants Strategic capital Revenue Production scale-up capex Regulatory trials R&D Opex spending 12 12 Strategic capital
Slide 16: Ambitions for 2030: Impact, scale and profitability
Ambitions for 2030: Impact, scale and profitability $200m+ 75k+ 35%+ ~0.5% Lifecare annual Patients treated per EBITDA margin Total share of CGM revenue annum target market
Slide 17: A platform built for more
A platform built for more Adding Expanding Building a geographies scope platform Targeted markets in MENA, India and Focus on lifestyle and prevention. Addressing multiple health conditions Pacific. Reaching 400M people in high- Addressing non-insulin dependent with the same core sensor density regi
Slide 18: Experienced and proven team driving Lifecare forward
Experienced and proven team driving Lifecare forward Executive leadership team 34 talented employees Joacim Holter Renete Kaarvik Andreas Pfützner Chief Executive Chief Financial Chief Scientific Officer Officer Officer Bergen, Norway Board and advisory team with strong track record Bristol, UK Main
Slide 19: Transforming diabetes care with implantable precision sensors
Transforming diabetes care with implantable precision sensors for continuous glucose monitoring Next-generation CGM Founded in 2006 6-month+, fully implantable, calibration- free glucose sensor solution HQ in Bergen, Norway Protected innovation Unique miniaturized system based on Specialized and osm
Slide 20: Summary
Summary ~ USD 5 billion Near-term value Capital-efficient path Peak revenue addressable market inflection points to commercialization potential of USD 1bn+ 20
Slide 21: Slide 21